Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page .
BMO Capital analyst David Lebowitz initiated coverage on Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) with an Outperform rating and announced a price target of $318. Alnylam Pharmaceuticals closed at $228.61 on Tuesday. See how other analysts view this stock. Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage on Agomab Therapeutics NV (NASDAQ: AGMB ) with an Overweight rating. AgomAb Therapeutics shares closed at $13.73 on Tuesday. See how other analysts view this stock . BMO Capital analyst David Lebowitz initiated coverage on Biomarin Pharmaceutical Inc (NASDAQ: BMRN ) with an Outperform rating and announced a price target of $98. BioMarin Pharmaceutical closed at $66.99 on Tuesday. See how other analysts view this stock . CLSA analyst Alvin Huang initiated coverage on KE Holdings Inc – ADR (NYSE: BEKE ) with an Outperform rating and announced a price target of $23.8. KE Holdings shares closed at $16.87 on Tuesday. See how other analysts view this stock . BMO Capital analyst David Lebowitz initiated coverage on Ionis Pharmaceuticals Inc (NASDAQ: IONS ) with a Market Perform rating and announced a price target of $60. Ionis Pharmaceuticals closed at $59.62 on Tuesday. See how other analysts view this stock.Considering buying ALNY stock? Here’s what analysts think:
Photo via Shutterstock
Latest Private Market Opportunities Join 400,000+ Investors Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Markets Trading Ideas Pre-Market Outlook News Analyst Ratings Initiation Top Initiations